Table 8 Selected first-line results from phase 1/2 trials in RET rearranged NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
Libretto-001 | NCT03157128 | Selpercatinib | 85 | 16.5 | NR |
ARROW | NCT03037385 | Praseltinib | 70 | 17.1 | NR |